Neha Krishnamohan

Board Member

Neha Krishnamohan joined our board of directors in September 2022. Ms Krishnamohan has over 15 years of experience in healthcare investment banking and financial and strategic leadership. She currently serves as the chief financial officer and chief business officer at Latigo Biotherapeutics, a clinical-stage biotechnology company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain. Most recently, she served as the chief financial officer and executive vice president of corporate development at Artiva Biotherapeutics (Nasdaq: ARTV), where she played a leadership role in their initial public offering. Prior to Artiva, she served as the chief financial officer and executive vice president of corporate development at Kinnate Biopharma Inc., a clinical-stage precision oncology company, where she led financial operations, business development, and investor relations and communications. She played a leadership role in Kinnate’s exploration of strategic alternatives, which resulted in an asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation.

Prior to Kinnate, Ms Krishnamohan was a vice president in the healthcare investment banking group and a member of the mergers and acquisitions (M&A) group within the investment banking division at Goldman Sachs. While at Goldman Sachs, she worked with biopharmaceutical boards and management teams on strategic financial matters, including financings and M&A transactions, and was one of the lead bankers on Arcutis’ 2020 initial public offering. Ms Krishnamohan has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors. Ms Krishnamohan holds a BSE with a double major in biomedical engineering and economics from Duke University.